Ontology highlight
ABSTRACT:
SUBMITTER: Adiwijaya BS
PROVIDER: S-EPMC5697569 | biostudies-other | 2017 Dec
REPOSITORIES: biostudies-other
Clinical pharmacology and therapeutics 20170605 6
Nanoliposomal irinotecan (nal-IRI) is a liposomal formulation of irinotecan with a longer half-life (t<sub>1/2</sub> ), higher plasma total irinotecan (tIRI), and lower SN-38 maximum concentration (C<sub>max</sub> ) compared with nonliposomal irinotecan. Population pharmacokinetic (PK) analysis of nal-IRI was performed for tIRI and total SN-38 (tSN38) using patient samples from six studies. PK-safety association was evaluated for neutropenia and diarrhea in 353 patients. PK-efficacy association ...[more]